Clinical Data ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis Pharmaceutical Technology48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.RespiratoryRead full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology 48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients. Respiratory Read full story Post navigation Previous: Remepy’s hybrid Parkinson’s therapy poised for phase 3Next: ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026